Why is "Juno Therapeutics" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-11 14:15:28
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Juno_Therapeutics entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-11 and was most recently seen on 2026-07-11.
Wikipedia Overview
Juno Therapeutics, Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Frequently asked questions about Juno Therapeutics - Fred Hutchinson Cancer Center
-
Juno's lasting legacy: How the cell therapy juggernaut influenced biotech in Seattle and beyond - GeekWire
-
U.S. FDA Grants Approval of Fourth CAR-T Cell Therapy (Breyanzi) to Juno Therapeutics - bioinformant.com
-
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold - The ASCO Post
-
TQ Therapeutics Acquires Juno Therapeutics - Contract Pharma
-
Dentons advises TQ Therapeutics on acquisition of Juno Therapeutics - Dentons
-
Juno Therapeutics Stops Trial Of Cancer-Killing Cells After 3 Patient Deaths - Forbes
-
Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership - PR Newswire
-
Juno Therapeutics Headquarters and R&D Facility, Washington - Pharmaceutical Technology
-
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017 - Fierce Biotech
-
Sloan Kettering and Juno Therapeutics win over $1.1 billion after jury verdict and post-trial motions in patent dispute with Kite Pharma/Gilead involving CAR-T therapy - Jones Day
-
Biotech’s Coming Cancer Cure - MIT Technology Review
-
Two patient deaths halt trial of Juno’s new approach to treating cancer - STAT
-
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform - PharmaTimes
-
Juno Therapeutics acquired by Celgene for $9B in dramatic deal for rising biotech star - GeekWire
-
Juno Therapeutics could shake up CAR-T market with strong lymphoma data - STAT
-
Amazon CEO Jeff Bezos backs cancer research startup Juno Therapeutics - GeekWire
-
Juno Therapeutics’ giant new Seattle HQ is designed to destroy cancer - GeekWire
-
Photos: Inside Juno Therapeutics’ new custom-built headquarters and cancer research labs - GeekWire
-
Juno Therapeutics vets Steve Harr and Hans Bishop on building startups, working with tech, and more - GeekWire
-
Juno executives investigated over trial deaths disclosure by law firm - Fierce Biotech
-
The $10 million molecule: Juno Therapeutics' acquisition of RedoxTherapies could improve cancer treatment - GeekWire
-
Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene - GeekWire
-
Celgene completes acquisition of Juno Therapeutics - The Seattle Times
-
Juno Therapeutics, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center announce new immuno-oncology clinical trials unit - Fred Hutchinson Cancer Center
-
Juno Therapeutics sued on securities fraud allegations following patient death - GeekWire
-
Juno Therapeutics to launch a new biotech company in China - The Business Journals
-
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer - CNBC
-
Celgene to Buy Juno Therapeutics for $9 Billion - WSJ
-
Cindy Elkins : Juno Therapeutics Chief Information Officer - Newsmakers - Leavey School of Business - SCU - Santa Clara University
-
Juno Therapeutics breaks ground on HQ, establishing a new hub for biotech in Seattle - GeekWire
-
Juno Therapeutics agrees to pay $24M to stockholders in suit over disclosure of patient deaths - GeekWire
-
Tech Moves: Ex-Juno CEO Hans Bishop takes over at Grail; Amazon Business chief departs; Shyft co-founder jumps to Ally; and more - GeekWire
-
Juno Therapeutics Buys Stage Cell Therapeutics for Up-to-$233M - Genetic Engineering and Biotechnology News
-
With Celgene buyout, Juno CEO Hans Bishop set for monster payout of $287M - Fierce Pharma
-
Why Celgene decided to buy Juno Therapeutics for $9B — with a little help from U.S. tax reform - GeekWire
-
Juno Therapeutics’ Rocket trial suspended after death - The Pharmaceutical Journal
-
Juno Therapeutics Cancer Trial Resumes, Pushing CAR-T Stocks Higher | Stock News & Stock Market Analysis - IBD - Investor's Business Daily
-
Three cancer research powerhouses form immunotherapy startup - Fred Hutchinson Cancer Center
-
TQ Therapeutics GmbH Announces Acquisition of Juno Therapeutics GmbH - Technology Networks
-
KEI asks FTC to block Celgene Acquisition of Juno Therapeutics, over BCMA-targeted CAR T treatment for Multiple Myeloma - Knowledge Ecology International
-
Celgene buys Juno for $9B, deepening bet on CAR-T - BioPharma Dive
-
Juno Therapeutics posts $66M Q2 loss, looks to gain ground with first clinical trials - GeekWire
-
Cancer immunotherapy company tries to explain deaths in recent trial - Science | AAAS
-
Celgene in Talks to Buy Juno Therapeutics - WSJ
-
Seattle's second-largest biotech unveils nine-story headquarters (Photos) - The Business Journals
-
Startup Spotlight: Juno, Vir alum starts a new immunotherapy company - STAT
-
JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A - Fierce Biotech
-
FDA dings Bristol Myers' CAR-T plant. Will it hurt liso-cel's approval prospects—and investors' CVR value? - Fierce Pharma
-
Juno Therapeutics ready for another round in war on cancer - The Seattle Times
-
Juno strikes deal to join bluebird, Novartis in busy multiple myeloma niche - Fierce Biotech
-
Juno investors eke out $24M settlement in lawsuit over CAR-T trial deaths - Fierce Pharma
-
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
-
Juno Therapeutics regroups after scuttling deadly flagship drug trial - The Business Journals
-
Behind the scenes at Juno's cancer immunotherapy manufacturing plant (Photos) - The Business Journals
-
'F*** Cancer' was this company's original name — and they have a 'no a**holes' policy, CEO says - GeekWire
-
Celgene to buy Juno for $9 billion to boost cancer pipeline - Reuters
-
Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer - GeekWire
-
Juno Therapeutics hires biotech vet in executive team expansion - The Business Journals
-
Kite Pharma, Juno duke it out in court over megamillion-dollar CAR-T patent - Fierce Pharma
-
In a surprise, Hans Bishop takes over as CEO of Grail, the liquid biopsy startup - STAT
-
Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results - thestreet.com
-
Celgene to buy Seattle biotech Juno for $9 billion to get promising cancer treatments - The Seattle Times
-
Juno plans to stay in Seattle after Celgene's $9 billion takeover - The Business Journals
-
3 Reasons Celgene's Investors Should Applaud the Juno Therapeutics Buyout - The Motley Fool
-
Celgene takes a punt on M&A to improve its pipeline and revenue chances - Chemistry World
-
Juno stock skyrockets after Celgene invests $1 billion to change the way cancer is treated - GeekWire
-
FDA halts Juno CAR-T trial after three patient deaths - Fierce Biotech
-
Former Juno execs unveil Sana, a new cell engineering biotech that’s reportedly raising more than $800M - GeekWire
-
Juno Completes $176M Series A Round - PR Newswire
-
Celgene research leader Dr. Rupert Vessey joins Juno board - The Business Journals
-
Juno halts its immunotherapy trial for cancer after three patient deaths - STAT
-
Juno CEO, CFO get additional 2015 bonuses after $1 billion Celgene deal - The Business Journals
-
The hottest thing in cancer drug development is a takeover target again — here's what you need to know about it - Business Insider
-
Cancer drug company snags Genenexer as R&D chief, plans Bay Area office - The Business Journals
-
How Juno's CEO broke the $9 billion takeover news to employees, vendors and founders - The Business Journals
-
Former Juno CEO Hans Bishop has $17M golden parachute thanks to Celgene takeover - The Business Journals
-
Celgene buys more Juno stock after failed flagship drug trial - The Business Journals
-
Ex-Juno leader becomes CEO of Alder BioPharmaceuticals ahead of migraine drug launch - The Business Journals
-
Juno CEO quietly steps down after $9 billion Celgene acquisition - The Business Journals
-
Juno Therapeutics (JUNO) Stock | Surges Despite Big Bio Selloff - warriortradingnews.com
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.